Detection in Fecal DNA of Colon Cancer–Specific Methylation of the Nonexpressed Vimentin Gene
Authors:
- Z. James HanZHZ. James Han
- Joel SkoletskyJSJoel Skoletsky
- Jeff OlsonJOJeff Olson
- Jerome SahJSJerome Sah
- Lois MyeroffLMLois Myeroff
- Petra PlatzerPPPetra Platzer
- Shilong LuSLShilong Lu
- Dawn DawsonDDDawn Dawson
- Joseph WillisJWJoseph Willis
- Theresa P. PretlowTPTheresa P. Pretlow
- James LutterbaughJLJames Lutterbaugh
Open Access
- 3 August 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 97 (15) , 1124-1132
Abstract
Background: Increased DNA methylation is an epigenetic alteration that is common in human cancers and is often associated with transcriptional silencing. Aberrantly methylated DNA has also been proposed as a potential tumor marker. However, genes such as vimentin, which are transcriptionally silent in normal epithelium, have not until now been considered as targets for cancer-associated aberrant methylation and for use as cancer markers. Methods: We applied methylation-specific polymerase chain reaction to the vimentin gene, which is transcriptionally silent in normal colonocytes, and compared methylation of vimentin exon 1 in cancer tissues and in fecal DNA from colon cancer patients versus control samples from healthy subjects. Results: Vimentin exon-1 sequences were unmethylated in 45 of 46 normal colon tissues. In contrast, vimentin exon-1 sequences were methylated in 83% (38 of 46) and 53% (57 of 107) of tumors from two independently collected groups of colon cancer patients. When evaluated as a marker for colon cancer detection in fecal DNA from another set of colon cancer patients, aberrant vimentin methylation was detected in fecal DNA from 43 of 94 patients, for a sensitivity of 46% (95% confidence interval [CI] = 35% to 56%). The sensitivity for detecting stage I and II cancers was 43% (26 of 60 case patients) (95% CI = 31% to 57%). Only 10% (20 of 198 case patients) of control fecal DNA samples from cancer-free individuals tested positive for vimentin methylation, for a specificity of 90% (95% CI = 85% to 94%). Conclusions : Aberrant methylation of exon-1 sequences within the nontranscribed vimentin gene is a novel molecular biomarker of colon cancer and can be successfully detected in fecal DNA to identify nearly half of individuals with colon cancer.Keywords
This publication has 27 references indexed in Scilit:
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Enhanced Retrieval of DNA from Human Fecal Samples Results in Improved Performance of Colorectal Cancer Screening TestThe Journal of Molecular Diagnostics, 2004
- Methylation changes in faecal DNA: a marker for colorectal cancer screening?The Lancet, 2004
- SLC5A8 , a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancersProceedings of the National Academy of Sciences, 2003
- The power and the promise of DNA methylation markersNature Reviews Cancer, 2003
- Focus on colon cancerCancer Cell, 2002
- HLTF gene silencing in human colon cancerProceedings of the National Academy of Sciences, 2002
- Cancer-epigenetics comes of ageNature Genetics, 1999
- Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.Proceedings of the National Academy of Sciences, 1996
- Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite InstabilityScience, 1995